19967-65-8

Upstream product

• 4303-29-1 4-thioxo-2-thiazolidinone 
• 41731-35-5 2‐bromo‐1,3‐thiazol‐4‐amine hydrobromide 

Downstream Products

• 19967-62-5 4-amino-5-(4-diethylamino-phenylimino)-5H-thiazol-2-one 
• 2295-31-0 thiazoline-2,4-dione 
• 19967-63-6 4-amino-5-(4-nitro-benzylidene)-5H-thiazol-2-one 
• 14513-16-7 4-anilino-5H-thiazol-2-one 
• 34551-16-1 4-α-Methylhydrazino-1,3-Δ³-thiazolin-2-on 
• 98408-20-9 4-methoxycarbonylimino-2-thiazolidinone 
• 1369321-32-3 4-(5,7-dimethyl-2-oxo-2,3-dihydrothiazolo[4,5-b]pyridin-6-ylazo)-N-thiazol-2-ylbenzenesulfonamide 
• 1369321-33-4 4-(5,7-dimethyl-2-oxo-2,3-dihydrothiazolo[4,5-b]pyridin-6-ylazo)-N-[1,3,4]thiadiazol-2-ylbenzenesulfonamide 
• 1369321-31-2 4-(5,7-dimethyl-2-oxo-2,3-dihydrothiazolo[4,5-b]pyridin-6-ylazo)benzoic acid 
• 1369321-24-3 5,7-dimethyl-6-o-tolylazo-3H-thiazolo[4,5-b]pyridin-2-one 
• 1369321-27-6 5,7-dimethyl-6-p-tolylazo-3H-thiazolo[4,5-b]pyridin-2-one 
• 1369321-30-1 5,7-dimethyl-6-(4-nitrophenylazo)-3H-thiazolo[4,5-b]pyridine-2-one 
• 1369321-23-2 5,7-dimethyl-6-phenylazo-3H-thiazolo[4,5-b]pyridin-2-one 

Relevant academic research and scientific papers

Synthesis and evaluation of anticancer activity of 5-ylidene-4-aminothiazol-2(5H)-one derivatives

The synthesis and antitumor activity screening of 4-aminothiazol-2(5H)-one derivatives were performed. The absence of possible 4-amino-imino tautomerism of thiazolidinones-2 has been confirmed based on the study of the molecule structures. The existence of the alone amino-form was confirmed. An anticancer activity screening was performed within the Developmental Therapeutics Program (National Cancer Institute/NIH, USA). Tested compounds possess low to moderate anticancer activity (average values - 60 cancer cell lines assay) with significant selective action on certain cancer cell lines (CCRF-CEM and RPMI-8226/leukemia, U251/CNS cancer, RFX 393/renal cancer, OVCAR/ovarian cancer etc.). The advantage of 5-ylidene-4-R-amino derivatives in comparison with compounds with free amino group was shown. Some structure-activity findings, the comparison of target compounds with isomeric 5-ylidene-2-imino(amino)thiazol-4(5H)-ones, as well as COMPARE analysis were described. Among the tested compounds (Z)-5-(furan-2-ylmethylidene)-4-(4-chlorophenylamino)thiazol-2(5H)-one (IIIk) and (Z)-5-(4-diethylaminophenylmethylidene)-4-(4-hydroxy-5-isopropyl-2-methylphenylamino)thiazol-2(5H)-one (IIIp) possessed the highest levels of activity.

PROPHYLACTIC OR THERAPEUTIC AGENT FOR CANCER

A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof has a superior activity as an estrogen-related receptor-α modulator, and is useful as a prophylactic or therapeutic agent for cancer.